Regulation - Research, Nephrology and Hepatology

Filter

Popular Filters

US orphan status for Pharmalink’s Busulipo

US orphan status for Pharmalink’s Busulipo

29-10-2013

Swedish specialty pharma group Pharmalink says its product Busulipo, (busulfan), a best-in-class conditioning…

BusulipoNefeconNephrology and HepatologyNorth AmericaOncologyPharmaceuticalPharmaLinkRegulationResearch

Keryx Biopharma rockets on new Zerenex data and plans to file for approval

29-01-2013

USA-based Keryx Biopharmaceuticals (Nasdaq: KERX) saw its shares close up a whopping 77% to $4.70 in…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenagelRenvelaResearchSanofiZerenex

Regulatory filing preparations underway for Vifor's PA21 on good Ph III results

09-07-2012

The pivotal Phase III clinical study shows that the new phosphate binder PA21 successfully controls hyperphosphatemia…

FreseniusGalenicaNephrology and HepatologyPA21PharmaceuticalRegulationResearchVifor Pharma

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial

04-01-2012

US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)) and partner Japanese drug major Astellas…

Astellas PharmaAVEO PharmaceuticalsBayerBiotechnologyNephrology and HepatologyNexavarOncologyPharmaceuticalRegulationResearchtivozanib

Isis sees Kynamro delay; adds new drugs to pipeline

15-12-2011

California, USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced yesterday that there will be a slight…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamromipomersenNephrology and HepatologyPharmaceuticalRegulationResearchSanofi

Parexel

Parexel

Back to top